Description
Cigna Corporation: Specialty Market Position & Biosimilars Strategy Driving Our Bullishness!
Cigna Group’s third-quarter 2024 earnings was decent and revealed shareholders’ net income of $739 million or $2.63 per share for the quarter. Notably, this figure was affected by a significant non-cash after-tax net realized investment loss of $1 billion related to VillageMD, resulting in a write-down of assets and an impairment charge. This has been excluded from adjusted operating income and earnings per share.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
